ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Saturday, November 16, 2024

10:30AM-12:30PM: Abstract Number: 0767

Comparing Large Vessel Uptake of 68Ga-HA-DOTATATE to 18F-FDG Using PET/CT Imaging in Patients with Active Giant Cell Arteritis

Vasculitis – Non-ANCA-Associated & Related Disorders Poster I

10:30AM-12:30PM: Abstract Number: 0679

Comparing Raynaud’s Phenomenon Measurement Tools: Results of the Optimizing Raynaud Phenomenon Outcome Measures in Systemic Sclerosis (ROSS) Study

Systemic Sclerosis & Related Disorders – Clinical Poster I

10:30AM-12:30PM: Abstract Number: 0618

Comparison of Cell Type-Specific Polygenic Risk in Systemic Lupus Erythematosus Patient and Healthy Controls

SLE – Diagnosis, Manifestations, & Outcomes Poster I

10:30AM-12:30PM: Abstract Number: 0233

Comparisons of Ga-FAPI and FDG PET/CT with X-ray Imaging in the Assessment of Rheumatoid Arthritis Patients

Imaging of Rheumatic Diseases Poster I: Inflammatory Arthritis

10:30AM-12:30PM: Abstract Number: 0461

Complete Description of the Three Pathways of the Complement System in a Series of 430 Patients with Rheumatoid Arthritis

RA – Diagnosis, Manifestations, & Outcomes Poster I

10:30AM-12:30PM: Abstract Number: 0009

Comprehensive Autoantibody Profiling Highlights Clinical Relevance of Autoantibodies to G Protein-coupled Receptors in Systemic Sclerosis: Insights from a B-cell Depletion Clinical Trial

B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster

10:30AM-12:30PM: Abstract Number: 0707

Comprehensive Skin Assessment in Systemic Sclerosis Using Spatial Frequency Domain Imaging (SFDI)

Systemic Sclerosis & Related Disorders – Clinical Poster I

10:30AM-12:30PM: Abstract Number: 0528

Consequences of Switching Originator Biological Therapies to Its Biosimilars in Patients with Immune-mediated Diseases in a Mexican Cohort

RA – Treatment Poster I

10:30AM-12:30PM: Abstract Number: 0026

Conserved Pro-Fibrotic Fibroblast Signatures in Osteoarthritis Synovium and Systemic Sclerosis Skin

Osteoarthritis & Joint Biology – Basic Science Poster

10:30AM-12:30PM: Abstract Number: 0479

Constructing and Using a Novel Nucleotide Transformer for Patients with Rheumatoid Arthritis

RA – Diagnosis, Manifestations, & Outcomes Poster I

10:30AM-12:30PM: Abstract Number: 0439

Contraception Counseling and Contraception Use Among SLE and RA/JIA Patients at a Public Medical Center in Los Angeles: Investigating Teratogenic Medication Use and Language Preferences

Reproductive Issues in Rheumatic Disorders Poster

10:30AM-12:30PM: Abstract Number: 0455

Contraception Counseling for Patients with Rheumatic and Musculoskeletal Diseases (RMDs) at a Tertiary Care Rheumatology Clinic: A Quality Improvement Project

Reproductive Issues in Rheumatic Disorders Poster

10:30AM-12:30PM: Abstract Number: 0417

Contraception in Community Rheumatology Practices

Reproductive Issues in Rheumatic Disorders Poster

10:30AM-12:30PM: Abstract Number: 0654

Corneal Confocal Microscopy: An Ophthalmic Imaging Biomarker for Small Fiber Neuropathy in Systemic Lupus Erythematosus

SLE – Diagnosis, Manifestations, & Outcomes Poster I

10:30AM-12:30PM: Abstract Number: 0495

Correlation Between Triglyceride/Glucose Index and Functional Capacity in Rheumatoid Arthritis Patients

RA – Diagnosis, Manifestations, & Outcomes Poster I

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].